Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Необходимость оценки риска остеопороза и переломов для своевременного назначения терапии
Необходимость оценки риска остеопороза и переломов для своевременного назначения терапии
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Клинические рекомендации по профилактике и ведению больных с остеопорозом. Под ред. О.М.Лесняк. Ярославль: Литера, 2012; с. 11–2.
2. Silvina L, George Th. Summary of AHRQ’s Comparative Effectiveness Review of Treatment to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis: Update of the 2007 Report. JMCP 2012; 18 (4 b).
3. Soong YK, Tsai KS, Huang HY et al. Risk of refracture associated with compliance a persistence with bisphosphonate therapy in Taiwan. Osteoporosis Int 2013; 24 (2): 511–21.
4. Yun H, Curtis JR, Saag K. Generic alendronate use among medicare beneficiaries: are part data complete? Pharmacoepidemiol Drug Saf 2013; 22 (1): 55–63.
5. Rizzoli R, Boonen S, Brandi ML et al. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008; 42: 246–9.
6. Boonen S, Vanderschueren D, Haentjens P, Lips P. Calcium and vitamin D in the prevention and treatment of osteoporosis – a clinical update. J Intern Med 2006; 259: 539–52.
7. Mehsen N, Paccou J, Confavreux CB et al. Management of patients with incident fractures during osteoporosis treatment. Joint Bone Spine 2010; 77: S133–S138.
8. Reymondier A, Caillet P, Abbas-Chorfa F et al. MENOPOST – Calcium and vitamin D supplementation in postmenopausal osteoporosis treatment: a descriptive cohort study. Osteoporos Int 2013; 24: 559–66.
9. Blotman F, Cortet B, Hilliquin P et al. Characterization of patients with postmenopausal osteoporosis in French primary healthcare. Drugs Aging 2007; 24: 603–14.
10. Lespessailles E, Cotté F-E, Roux C et al. Prevalence and features of osteoporosis in the French general population: the Instant study. Joint Bone Spine 2009; 76: 394–400.
11. Fardellone P, Mann B. Co-prescription of calcium and/or vitamin D with once weekly bisphosphonate therapy: findings from a French longitudinal patient database. Osteoporos Int 2007; 18 (Suppl. 1): 358.
12. Adami S, Giannini S, Bianchi G et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20: 239–44.
13. Bayly JR, Hollan ds RD, Riordan-Jones SE et al. Pre-scribed vitamin D and calcium preparations in patients treated with bone remodelling agents in primary care: a report of a pilot study. Curr Med Res Opin 2006; 22: 131–7.
14. Quesada JM, Mann B. Low usage of calcium and vitamin D with bisphosphonate therapy in post-menopausal osteoporotic women in France and in Spain. Osteoporos Int 2007; 18 (Suppl. 1): 354.
15. Hanley DA, Zhang Q, Meilleur M-C et al. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada. Curr Med Res Opin 2007; 23: 1473–80.
16. Fardellone P, Cotté F-E, Roux C et al. Calcium intake and the risk of osteoporosis and fractures in French women. Joint Bone Spine 2010; 77: 154–8.
17. Kanis JA, McCloskey EV, Johansson H et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24: 23–57.
18. Торопцова Н.В., Никитинская О.А. Лечение остеопороза: клинический опыт применения дженерического препарата. Соврем. ревматология. 2011; 1: 28–32.
2. Silvina L, George Th. Summary of AHRQ’s Comparative Effectiveness Review of Treatment to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis: Update of the 2007 Report. JMCP 2012; 18 (4 b).
3. Soong YK, Tsai KS, Huang HY et al. Risk of refracture associated with compliance a persistence with bisphosphonate therapy in Taiwan. Osteoporosis Int 2013; 24 (2): 511–21.
4. Yun H, Curtis JR, Saag K. Generic alendronate use among medicare beneficiaries: are part data complete? Pharmacoepidemiol Drug Saf 2013; 22 (1): 55–63.
5. Rizzoli R, Boonen S, Brandi ML et al. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008; 42: 246–9.
6. Boonen S, Vanderschueren D, Haentjens P, Lips P. Calcium and vitamin D in the prevention and treatment of osteoporosis – a clinical update. J Intern Med 2006; 259: 539–52.
7. Mehsen N, Paccou J, Confavreux CB et al. Management of patients with incident fractures during osteoporosis treatment. Joint Bone Spine 2010; 77: S133–S138.
8. Reymondier A, Caillet P, Abbas-Chorfa F et al. MENOPOST – Calcium and vitamin D supplementation in postmenopausal osteoporosis treatment: a descriptive cohort study. Osteoporos Int 2013; 24: 559–66.
9. Blotman F, Cortet B, Hilliquin P et al. Characterization of patients with postmenopausal osteoporosis in French primary healthcare. Drugs Aging 2007; 24: 603–14.
10. Lespessailles E, Cotté F-E, Roux C et al. Prevalence and features of osteoporosis in the French general population: the Instant study. Joint Bone Spine 2009; 76: 394–400.
11. Fardellone P, Mann B. Co-prescription of calcium and/or vitamin D with once weekly bisphosphonate therapy: findings from a French longitudinal patient database. Osteoporos Int 2007; 18 (Suppl. 1): 358.
12. Adami S, Giannini S, Bianchi G et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20: 239–44.
13. Bayly JR, Hollan ds RD, Riordan-Jones SE et al. Pre-scribed vitamin D and calcium preparations in patients treated with bone remodelling agents in primary care: a report of a pilot study. Curr Med Res Opin 2006; 22: 131–7.
14. Quesada JM, Mann B. Low usage of calcium and vitamin D with bisphosphonate therapy in post-menopausal osteoporotic women in France and in Spain. Osteoporos Int 2007; 18 (Suppl. 1): 354.
15. Hanley DA, Zhang Q, Meilleur M-C et al. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada. Curr Med Res Opin 2007; 23: 1473–80.
16. Fardellone P, Cotté F-E, Roux C et al. Calcium intake and the risk of osteoporosis and fractures in French women. Joint Bone Spine 2010; 77: 154–8.
17. Kanis JA, McCloskey EV, Johansson H et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24: 23–57.
18. Торопцова Н.В., Никитинская О.А. Лечение остеопороза: клинический опыт применения дженерического препарата. Соврем. ревматология. 2011; 1: 28–32.
Авторы
О.А.Никитинская, Н.В.Торопцова
ФГБУ Научно-исследовательский институт ревматологии им. В.А.Насоновой РАМН, Москва
ФГБУ Научно-исследовательский институт ревматологии им. В.А.Насоновой РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.